In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss leadership in eye care with guest Jack T. Holladay, MD, MSEE, FACS.

Brought to you by Johns Hopkins University.
•  Welcome to the Eyeluminaries podcast :21
•  Review of episode 23 1:19
•  Blog by John A. Hovanesian, MD, FACS 3:10
•  Merck to acquire EyeBio 4:14
•  FDA approves aflibercept biosimilars Yesafili, Opuviz 6:26
•  Aurion Biotech completes enrollment in phase 1/2 corneal edema cell therapy trial 8:43
•  Intro of Jack Holladay, MD, MSEE 11:10
•  How did you develop a passion for optics? Did you know it was going to be your future? 13:50
•  Holladay’s life-threatening situation 16:21
•  Holladay’s experience teaching residents 23:50
•  Holladay’s optics strategy for improving his golf game 28:33
•  Preview of episode 25 32:25
•  Feedback, questions and guest suggestions at [email protected] 32:45

Jack T. Holladay, MD, MSEE, FACS, is a clinical professor of ophthalmology at Baylor College of Medicine and retired from clinical ophthalmic practice.

John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.

We’d love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian.

Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus.